About Elicityl
Elicityl is a company based in Crolles (France) founded in 2002. Elicityl has raised $136.86 thousand across 1 funding round from investors including Succes Europe. Elicityl offers products and services including Bioactive Oligosaccharides, Glycoconjugates, Polysaccharides, and R&D Services. Elicityl operates in a competitive market with competitors including GlyTech, Iceni Glycoscience, Echelon Biosciences, Avanti Polar Lipids and TFChem, among others.
- Headquarter Crolles, France
- SectorsHealthcare
- Website elicityl-oligotech.com
- Social LinkedIn X YouTube
- Legal Name Elicityl S.A.
- Total Equity Funding$136.86K (USD)
in 1 rounds
- Latest Funding Round$136.86K (USD), Seed
Sep 2010
- Investors
Products & Services of Elicityl
Elicityl offers a comprehensive portfolio of products and services, including Bioactive Oligosaccharides, Glycoconjugates, Polysaccharides, and R&D Services.
Products for glycobiology research and applications in health.
Functionalized oligosaccharides for scientific and industrial uses.
Compounds for agriculture and nutrition applications.
Custom synthesis and purification for biomolecules.
Apps and channels of Elicityl
its YouTube channel Elicityl has 0026 subscribers and 1 videos.
Videos from Elicityl
The most watched videos on Elicityl's YouTube channel, Elicityl (0026 subscribers). Click a video to play it here.
More on Elicityl.
Funding Insights of Elicityl
Elicityl has successfully raised a total of $136.86K through 1 strategic funding round. The most recent funding activity was a Seed round of $136.86 thousand completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $136,856
- Total Rounds 1
- Last Round Seed — $136,856
- First Round $136,856
(Sep 2010)
- Investors Count 1
All 1 funding rounds of Elicityl with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2010 | $136,856 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Elicityl
Elicityl has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Succes Europe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | succes-europe.com | - |
Investor details for Elicityl
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Elicityl
2 dated milestones of Elicityl across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Elicityl is founded.
- Funding First funding round of $137K.
Competitors of Elicityl
Elicityl operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GlyTech, Iceni Glycoscience, Echelon Biosciences, Avanti Polar Lipids and TFChem, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| glytech-inc.com | 2012 | Kyoto, Japan | $9.14M | – | Human-type Asp-linked glycans are supplied for research applications. | |
| iceniglycoscience.com | 2014 | Norwich, United Kingdom | $1.77M | 16 | Glycoscience platform is provided for diagnostic and therapeutic applications. | |
| echelon-inc.com | 1997 | Salt Lake, United States | – | – | Reagents and assays for lipid biology research are manufactured. | |
| avantilipids.com | 1969 | Alabaster, United States | – | 134 | Phospholipids and lipids are manufactured for life science applications. | |
| tfchemistry.com | 2007 | Rouen, France | – | – | Fluoride chemistry is utilized to design glycomimetic drug compounds. | |
| glycospot.dk | 2014 | Frederiksberg, Denmark | $3.58M | 13 | High-throughput enzyme screening solutions are developed and provided. | |
| addaxbio.com | 2017 | Turin, Italy | – | – | Developer of a non-toxic formalin alternative tissue fixative. This fixative provides comparable or superior results to formalin in histological, immunohistochemical, and molecular analyses, while eliminating the carcinogenic and toxic risks associated with formalin use. The product is protected by an international patent and is designed for use in histology laboratories, improving both patient care and worker safety. The company collaborates with various research institutions to advance the application of this technology in different fields. | |
| enzabiotech.com | 2012 | Lund, Sweden | – | – | Biobased nonionic surfactants are developed for various applications. | |
| prozyme.com | 1990 | Hayward, United States | – | – | Biochemical reagents and services for glycosciences are provided. |
Detailed competitors of Elicityl
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Elicityl
The website of Elicityl (elicityl-oligotech.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 48.4% vs previous month
Similar companies to Elicityl
10 companies that operate in the same segment as Elicityl (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Elicityl
Elicityl was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Elicityl is headquartered in Crolles, France. It is registered at Crolles, Isere, France.
Elicityl is a funded company, having raised a total of $136.86K across 1 funding round to date. The company's 1st funding round was a Seed of $136.86K, raised on Sep 2010.
ELICITYL is a provider of glyco products for the agriculture, cosmetics, nutraceutical and pharmaceutical markets. The companys two primary offerings include OligoTech, a library of complex carbohydrates and glycoproducts, (which are extracted from biomass and are produced through bacterial fermentation and chemical functionalization), and PEL101GV, a complex sugar extracted from biomass that helps in enhancing the natural vine resistance to spring frosts. The company claims to be coordinating CARBINFEC, an industrial consortium to create a bank of complex sugars with antiviral activity. (Hepatitis C, influenza, and dengue viruses).
Elicityl's top competitors include GlyTech, Echelon Biosciences and Iceni Glycoscience.
Elicityl offers Bioactive Oligosaccharides, Glycoconjugates, Polysaccharides, and R&D Services.
Elicityl has 1 investor. Key investors include Succes Europe.
Elicityl operates through Elicityl S.A..